. Author manuscript; available in PMC: 2019 Jun 27.

Published in final edited form as: J Urol. 2018 Jan 31;199(6):1470–1474. doi: 10.1016/j.juro.2018.01.070

Table 2.

Meta-analytic results comparing a model of total PSA, free PSA, age and DRE (available) with and without intact PSA and hK2.

	Model without intact PSA and hK2	Model including intact PSA and hK2	Difference
Cohort	AUC (95% CI)	AUC (95% CI)	Increase in AUC (95% CI)
Goteborg 1^st Round	0.749 (0.636, 0.861)	0.900 (0.837, 0.964)	0.151 (0.052, 0.251)
Goteborg 2^nd Round	0.675 (0.590, 0.760)	0.796 (0.730, 0.862)	0.121 (0.054, 0.188)
Rotterdam 1^st Round	0.807 (0.772, 0.842)	0.859 (0.828, 0.889)	0.052 (0.024, 0.079)
Rotterdam 2-3^rd Round	0.744 (0.682, 0.805)	0.797 (0.748, 0.847)	0.053 (0.002, 0.105)
Rotterdam Repeat Biopsy	0.861 (0.759, 0.963)	0.883 (0.803, 0.963)	0.022 (−0.050, 0.094)
Tarn	0.763 (0.683, 0.844)	0.857 (0.798, 0.916)	0.093 (0.032, 0.155)
ProtecT	0.734 (0.713, 0.756)	0.799 (0.781, 0.818)	0.065 (0.047, 0.083)
UPCA	0.703 (0.652, 0.755)	0.765 (0.718, 0.812)	0.062 (0.022, 0.101)
Opko	0.717 (0.675, 0.760)	0.805 (0.771, 0.840)	0.088 (0.056, 0.120)
Veterans Affairs	0.659 (0.591, 0.726)	0.751 (0.693, 0.810)	0.092 (0.042, 0.142)
Overall (fixed effects estimate)	0.742 (0.727, 0.756)	0.813 (0.801, 0.825)	0.069 (0.057, 0.080)
Overall (random effects estimate)	0.739 (0.707, 0.770)	0.818 (0.792, 0.844)	0.071 (0.056, 0.085)